Enterprise Value
0.00
Cash
59.01M
Avg Qtr Burn
N/A
Short % of Float
11.29%
Insider Ownership
5.50%
Institutional Own.
83.29%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
VONJO (Pacritinib) (JAK2 oral kinase inhibitor) Details Myelofibrosis, Solid tumor/s, Cancer | Approved Quarterly sales |